Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model

In a Phase III trial for HER2-positive breast cancer (the CLEOPATRA study), the triple-drug combination arm of pertuzumab plus trastuzumab plus docetaxel showed significantly longer progression-free survival and overall survival than did the trastuzumab plus docetaxel arm. In this study, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita-Kashima, Yoriko, Shu, Sei, Yorozu, Keigo, Moriya, Yoichiro, Harada, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607650/
https://www.ncbi.nlm.nih.gov/pubmed/28959366
http://dx.doi.org/10.3892/ol.2017.6679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607650/
https://www.ncbi.nlm.nih.gov/pubmed/28959366
http://dx.doi.org/10.3892/ol.2017.6679

Ejemplares similares